Vonsetamig

Phase 1Small molecule

Regeneron

Vonsetamig is one of 68 small molecule programs targeting Chronic Kidney Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Kidney DiseaseActive, not recruiting

Lupus NephritisActive, not recruiting

Lupus Nephritis (LN)Recruiting

Chronic Kidney DiseasePhase 1/Phase 2

Active, not recruiting

Lupus NephritisPhase 1

Active, not recruiting

Lupus Nephritis (LN)Phase 1

Recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Glucotrol

Pfizer

Preclinical

1 4

Vemlidy

Gilead

Preclinical

1 5

Activase

Flomax

Epoetin Beta

5 8

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

PROCRIT

WWim Janssens

Preclinical

1 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Chronic Kidney Disease

NCT05092347

Q3 2029

Phase 1Recruiting

Lupus Nephritis (LN)

NCT06975787

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

Recruiting· Regeneron logo

Regeneron·Phase 1/2·NCT05092347·56 enrolled

Lupus Nephritis (LN)1 trial

A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis

Recruiting· Regeneron logo

Regeneron·Phase 1·NCT06975787·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Vonsetamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vonsetamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vonsetamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Regeneron

Vonsetamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2029

Trials by Indication[1]

Chronic Kidney Disease1 trial

Lupus Nephritis (LN)1 trial

References

Drug Info

Quick Facts

Related News